瑞财经 刘治颖近日，信邦制药(SZ002390)发布2024年年度报告，营收净利双降。 2024年，信邦制药营业收入为60.32亿元，同比减少6.63%；归属于上市公司股东的净利润1.01亿元，同比减少64.7%； 归属于上市公司股东的扣除非经常性损益的净利润1.65亿元，同比减少38.29%。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 6,032,262,052.57 | 6,460,841,315,46 | -6.63% | 6,350,025,827.03 | | 归属于上市公司股东的净利润 | 101,381,622.75 | 287,232,798.94 | -64.70% | 224,374,022.03 | | (元) | | | | | | 归属于上市公司股东的扣除非经常 性频益的净利润(元) | 165,318,585.59 | 267,902,516.17 | -38.29% | 224,317,549.11 | | 经营活动产生的现金流量净额 (元) | 634, ...

Core Insights - The company reported a total revenue of 6.032 billion yuan in 2024, a year-on-year decline of 6.63%, with a net profit attributable to shareholders of 101 million yuan, down 64.70% year-on-year [1] - The core business segments include medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing, but the overall performance in 2024 was disappointing [1] Medical Services Segment - The medical services segment generated revenue of 1.636 billion yuan, a decrease of 8.48% year-on-year, with tumor hospital revenue at 792 million yuan and general hospital revenue at 845 million yuan [4] - Despite the revenue decline, the company made progress in medical quality, refined management, and brand building [4] - Initiatives included optimizing medical quality management, enhancing multi-disciplinary treatment models, and achieving significant academic contributions with 261 published articles, including 40 in SCI journals [4] Pharmaceutical Distribution Segment - The pharmaceutical distribution segment achieved revenue of 4.746 billion yuan, down 10.03% year-on-year, with drug revenue at 4.159 billion yuan and medical device revenue at 587 million yuan [6] - The company focused on customer structure adjustment and channel optimization to improve asset safety and fund efficiency [6] - Notable growth was seen in the DTP specialty pharmacy sales, which exceeded 100 million yuan, marking a 60% increase year-on-year [6] Pharmaceutical Manufacturing Segment - The pharmaceutical manufacturing segment reported revenue of 939 million yuan, an increase of 11.28% year-on-year, with traditional Chinese medicine pieces revenue at 622 million yuan, up 18.74% [7] - The company enhanced market management through commercial channel restructuring and training, achieving internal management efficiency [7] - The development and launch of new health products were completed, and the company implemented a traceability system for traditional Chinese medicine to ensure quality [7] Overall Performance and Future Outlook - Despite facing significant performance pressure in 2024, the company made strides in refined management and brand building across its three main segments [8] - Future efforts will be needed to improve operational efficiency and respond to market changes to tackle challenges posed by the industry environment [8]

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 国家药监局3月批准注册308个医疗器械产品 4月14日消息，国家药监局2025年3月共批准注册医疗器械产品308个。其中，境内第三类医疗器械产品 248个，进口第三类医疗器械产品34个，进口第二类医疗器械产品19个，港澳台医疗器械产品7个。 药械审批 成都赛璟生物熊去氧胆酸口服混悬液获批上市 近日，成都赛璟生物研发的熊去氧胆酸口服混悬液作为国内首仿3.1类新药，正式获批上市。熊去氧胆 酸由德国Dr.Falk Pharma GmbH原研，包含了片剂、胶囊、口服混悬剂等剂型。据介绍，本次获批产品 是国内企业首个且唯一获批治疗罕见病囊性纤维化相关肝病(CFALD)的药物，填补了国内目前上市的熊 去氧胆酸片剂/胶囊剂无此适应证的空白。 21点评：世界卫生组织表明，约80%男人和女人一生中会感染至少一种HPV型别。HPV对外界的抵抗力 相对较强；性行为是感染HPV的主要途径，但不是唯一途径，HPV的感染还可通过母婴传播以及直接接 触传播，如皮肤黏膜接触。长期以来，HPV疫苗主要针对女性，用于预防宫颈癌。这一获批也将提 ...

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

贵州信邦制药股份有限公司 2024年度独立董事述职报告（刘一烽） 作为贵州信邦制药股份有限公司（以下简称"公司"）2024 年度 新任独立董事，本人严格按照《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司治理准则》、《上市公司独立董事管理办法》 等有关法律、法规、规范性文件及《公司章程》、《独立董事工作制 度》的有关规定，尽职尽责，忠实、勤勉地履行独立董事义务，积极 出席相关会议，认真审议董事会各项议案，充分发挥了独立董事的独 立作用，切实维护了公司及全体投资者，尤其是中小投资者的合法权 益。 报告期内，本人经公司于 2024 年 2 月 20 日召开的 2024 年第二 次临时股东大会选举成为公司新任独立董事，在任职后履行公司独立 董事及相关董事会专门委员会的职责。现就本人 2024 年度任职期间 履行独立董事职责情况述职如下： 一、基本情况 本人刘一烽，中国籍，1971 年出生，无境外永久居留权，四川大 学工商管理硕士，现任贵州黄果树立爽药业有限公司董事，副总经理 兼营销总监。自 2024 年 2 月至今任公司独立董事。 本人对报告期内 ...

贵州信邦制药股份有限公司 2024年度独立董事述职报告（邱刚） 作为贵州信邦制药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司治理准则》、《上市公司独立董事管理办法》等有关法律、法规、 规范性文件及《公司章程》、《独立董事工作制度》的有关规定，尽 职尽责，忠实、勤勉地履行独立董事义务，积极出席相关会议，认真 审议董事会各项议案，充分发挥了独立董事的独立作用，切实维护了 公司及全体投资者，尤其是中小投资者的合法权益。现就本人 2024 年度履行独立董事职责情况述职如下： 一、基本情况 本人邱刚，中国籍，1967 年出生，无境外永久居留权，大学本科 学历，拥有法律职业资格证书，政协贵州省第十三届委员，贵州省工 商联第十三届执委，民建贵州省委法制委主任，最高人民检察院民事 行政检察咨询专家，贵阳仲裁委员会仲裁员，现任贵州中创联律师事 务所主任、律所管委会主任。自 2021 年 7 月至今任公司独立董事。 本人对报告期内任职独立性情况进行了自查，并将独立性自查情 况提交董事会。经自查，本人 ...

贵州信邦制药股份有限公司 2024年度独立董事述职报告（周俊-离任） 作为贵州信邦制药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司治理准则》、《上市公司独立董事管理办法》等有关法律、法规、 规范性文件及《公司章程》、《独立董事工作制度》的有关规定，尽 职尽责，忠实、勤勉地履行独立董事义务，积极出席相关会议，认真 审议董事会各项议案，充分发挥了独立董事的独立作用，切实维护了 公司及全体投资者，尤其是中小投资者的合法权益。现就报告期内本 人任职期间履行独立董事职责情况述职如下： 一、基本情况 本人周俊，中国籍，1968 年出生，无境外永久居留权，华东理工 大学制药专业学士，格勒诺布尔大学 EMBA，曾任成都倍特药业股份有 限公司副总经理，上海腾瑞制药有限公司商业运营总裁，中美上海施 贵宝制药有限公司OTC 事业部总经理、抗病毒事业部全国销售总监。 自 2023 年 11 月至 2024 年 2 月任公司独立董事。2024 年 2 月公司董 事会换届，本人不再担任公司独立董事。 二、履 ...

2024年度独立董事述职报告（刘杰） 贵州信邦制药股份有限公司 作为贵州信邦制药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司治理准则》、《上市公司独立董事管理办法》等有关法律、法规、 规范性文件及《公司章程》、《独立董事工作制度》的有关规定，尽 职尽责，忠实、勤勉地履行独立董事义务，积极出席相关会议，认真 审议董事会各项议案，充分发挥了独立董事的独立作用，切实维护了 公司及全体投资者，尤其是中小投资者的合法权益。现就本人 2024 年度履行独立董事职责情况述职如下： 一、基本情况 本人刘杰，中国籍，1979 年出生，无境外永久居留权，厦门大学 会计学博士，贵州财经大学教授，华北水利水电大学兼职教授，现任 贵阳市税务学会副会长兼理事、中国贵州茅台酒厂（集团）有限责任 公司外部董事、贵阳观山湖投资发展控股有限公司外部董事、贵州三 都农村商业银行股份有限公司独立董事、贵州省交通规划勘察设计研 究院股份有限公司独立董事、云岩区黔灵医院财务顾问。自 2023 年 5 月至今任公司独立董事。 ...

证券代码：002390 证券简称：信邦制药 公告编号：2025-010 贵州信邦制药股份有限公司 关于续聘公司2025年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 3、诚信记录 贵州信邦制药股份有限公司（以下简称"公司"）于2025年4月11 日召开的第九届董事会第六次会议、第九届监事会第六次会议审议通 过了《关于续聘公司2025年度审计机构的议案》，本事项尚需提交公 司2024年度股东大会审议。现将有关事宜公告如下： 一、拟聘任会计师事务所的基本信息 （一）机构信息 | 机构名称 | 北京德皓国际会计师事务所（特殊普通合伙） | | --- | --- | | 成立日期 | 2008年12月8日成立 | | 组织形式 | 特殊普通合伙 | | 注册地址 | 北京市西城区阜成门外大街 31 号 5 层 519A | | 首席合伙人 | 杨雄 | | 截至2022年12月31日合伙人数量 | 66人 | | 截至2022年12月31日注册会计师人数 | 300人 | | 其中：签署过证券服务业务审计报告的注 册会计师人数 | 140人 | ...

贵州信邦制药股份有限公司 董 事 会 二〇二五年四月十一日 根据中国证券监督管理委员会《上市公司独立董事管理办法》、 《深圳证券交易所股票上市规则》、《上市公司自律监管指引第 1 号— —主板上市公司规范运作》等相关法律、法规的要求，贵州信邦制药 股份有限公司（以下简称"公司"）董事会对公司在任独立董事邱刚 先生、刘杰先生、刘一烽先生的独立性情况进行评估并出具如下专项 意见： 经核查独立董事邱刚先生、刘杰先生、刘一烽先生的任职情况以 及其签署的自查报告，上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东单位担任任何职务，与公司及其主要股东、 实际控制人之间不存在利害关系或其他可能妨碍其进行独立客观判 断的关系，符合《上市公司独立董事管理办法》、《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法 律、法规对独立董事独立性的要求。 贵州信邦制药股份有限公司董事会 对独立董事独立性评估情况的专项意见 ...